ClinicalTrials.gg
CompletedNCT00882440Updated Aug 27, 2015Results posted

A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)

A Phase 3 interventional study of losartan potassium and Placebo in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
576
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
6th of 65
576 · median 100
Started
1990
the only one that year
Phase 3
17 of 65
1 open now
Registered
17th of 65
by date
Lead sponsor
6 of 65
Merck Sharp & Dohme LLC

Among the 65 studies testing losartan in Hypertension, this one is the 6th largest by enrollment, is the only one that started in 1990, is one of 17 in phase 3, and was the 17th registered.

Hypertension

6,120 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study was to compare the antihypertensive efficacy of different doses of losartan compared to placebo and enalapril, in patients with supine diastolic blood pressure of 100-115 mmHg.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has been diagnosed with mild to moderate hypertension, with supine diastolic blood pressure of 100 to 115 mmHg
  • Patient has no active medical problems other than essential hypertension that might affect blood pressure
  • Patient has received no drug therapy that might affect blood pressure

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to losartan
  • History of stroke
  • History of myocardial infarction
  • Atrial flutter or atrial fibrillation
  • History of congestive Heart failure
  • Known Sensitivity to ACE inhibitors
  • Known positive test for /AIDS or
  • Patient is being treated for acute ulcer disease
  • History of chronic liver disease
  • Actively treated diabetes mellitis
  • Any known bleeding or disorder
  • Absence of one kidney
  • Women of or who are breastfeeding
  • Patient is abusing or has a history of alcoholism or drug addiction
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
576 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Placebo

  • Experimental
    2

    Losartan 10 mg

    Drug: losartan potassium

  • Experimental
    3

    Losartan 25 mg

    Drug: losartan potassium

  • Experimental
    4

    Losartan 50 mg

    Drug: losartan potassium

  • Experimental
    5

    Losartan 100 mg

    Drug: losartan potassium

  • Experimental
    6

    Losartan 150 mg

    Drug: losartan potassium

  • Active comparator
    7

    Enalapril 20 mg

    Drug: Enalapril

Interventions

  • losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks

    Also known as: MK0954, Cozaar

  • DrugPlacebo

    Placebo capsule to losartan

  • Enalapril 20 mg oral tablet taken once daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8

    Time frame: 24 hours post dose at Baseline and Week 8

Secondary outcomes

  1. Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8

    Patients in Category I (defined as "excellent" in protocol) if SuDBP was \<90 mmHg, Category II (defined as "good" in protocol) if SuDBP was ≥90 but decreased at least 10 mmHg, or Category III (defined as "fair" or "inadequate" in protocol) if SuDBP was ≥90 and decreased less than 10 mmHg.

    Time frame: 24 hours post dose at Week 8

  2. Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8

    Time frame: 6 hours post dose at Baseline and 8 weeks

07

Results

Posted Jun 10, 2009

Participant flow

Patients were recruited at 28 sites in the United States. Primary Therapy Period: December, 1990-August, 1991

Participant flow — Overall Study
MilestonePlaceboLosartan 10 mgLosartan 25 mgLosartan 50 mgLosartan 100 mgLosartan 150 mgEnalapril 20
Started78808279908483
Completed67727576807779
Not completed118731074
Withdrew: Adverse event2221142
Withdrew: Lack of efficacy3520030
Withdrew: Lost to follow-up2011101
Withdrew: Protocol violation0011100
Withdrew: Withdrawal by subject2110601
Withdrew: Patient uncooperative2000100

Outcome measures

SecondaryCategories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8

Patients in Category I (defined as "excellent" in protocol) if SuDBP was \<90 mmHg, Category II (defined as "good" in protocol) if SuDBP was ≥90 but decreased at least 10 mmHg, or Category III (defined as "fair" or "inadequate" in protocol) if SuDBP was ≥90 and decreased less than 10 mmHg.

Time frame:
24 hours post dose at Week 8
Reported as:
Number · Participants
Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8
ParticipantsPlaceboLosartan 10 mgLosartan 25 mgLosartan 50 mgLosartan 100 mgLosartan 150 mgEnalapril 20
Category I10192124292835
Category II1417715191216
Category III54445439414431
PrimaryMean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8
Time frame:
24 hours post dose at Baseline and Week 8
Reported as:
Mean · mm Hg
Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8
mm HgPlaceboLosartan 10 mgLosartan 25 mgLosartan 50 mgLosartan 100 mgLosartan 150 mgEnalapril 20
Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8-5.6 ± 7.8-7.9 ± 7.6-6.8 ± 7.9-10.1 ± 7.0-9.9 ± 6.9-9.7 ± 8.0-11.2 ± 6.7
SecondaryMean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8
Time frame:
6 hours post dose at Baseline and 8 weeks
Reported as:
Mean · mm Hg
Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8
mm HgPlaceboLosartan 10 mgLosartan 25 mgLosartan 50 mgLosartan 100 mgLosartan 150 mgEnalapril 20
Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8-4.7 ± 8.7-7.3 ± 9.4-9.9 ± 8.5-11.9 ± 9.2-10.4 ± 8.9-13.1 ± 9.0-16.2 ± 10.4

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboLosartan 10 mgLosartan 25 mgLosartan 50 mgLosartan 100 mgLosartan 150 mgEnalapril 20Total
Mean52.3 ± 11.653.9 ± 12.352.8 ± 12.252.8 ± 10.354.0 ± 10.253.9 ± 10.851.9 ± 11.153.1 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLosartan 10 mgLosartan 25 mgLosartan 50 mgLosartan 100 mgLosartan 150 mgEnalapril 20Total
Female31292726312227193
Male47515553596256383
Race/Ethnicity
Race/Ethnicity(participants)PlaceboLosartan 10 mgLosartan 25 mgLosartan 50 mgLosartan 100 mgLosartan 150 mgEnalapril 20Total
Caucasian64606357666464438
Black51014111711775
Hispanic99511781059
Other01000124
SuDBP
SuDBP(mmHg)PlaceboLosartan 10 mgLosartan 25 mgLosartan 50 mgLosartan 100 mgLosartan 150 mgEnalapril 20Total
Mean103.3 ± 3.8104.3 ± 3.9103.3 ± 3.7104.0 ± 3.7104.1 ± 4.2103.4 ± 3.4103.1 ± 3.7103.7 ± 3.8
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995 Jun;25(6):1345-50. doi: 10.1161/01.hyp.25.6.1345. PubMed 7768585 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 1990, a primary completion of Aug 1991 and a completion of Jan 1992. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 17 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2009
First posted
Apr 16, 2009
Start
Dec 1990
Primary completionActual
Aug 1991
CompletionActual
Jan 1992
Results first posted
Jun 10, 2009
Last update
Aug 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00882440
Responsible party
Sponsor
First posted
Apr 16, 2009
Start date
Dec 1990
Primary completion
Aug 1991
Completion
Jan 1992
Results posted
Jun 10, 2009
Last update
Aug 27, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion